Trial Profile
A trial to analyze the differences in adherence and persistence in patients receiving fingolimod (FTY) and dimethyl fumarate (DMF) for treatment of relapsing-remitting multiple sclerosis over 1 year
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 03 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology